ADAM17 Fluorogenic Assay Kit

Catalog #
78000
$465 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The key to the ADAM17 Fluorescent Assay Kit is the fluorogenic substrate. Using this kit, only one simple step on a microtiter plate is required for ADAM17 reactions. A sample containing ADAM17 is incubated in a reaction mixture with the fluorogenic substrate and fluorescence (λex = 485 nm, λem = 530 nm) is measured using a plate reader.

Need us to run inhibitor screens or profile your compounds against ADAM17? Check out our Protease Screening Services.

This product has been cited 1 time.

Synonyms
Disintegrin And Metalloproteinase Domain-Containing Protein, Tumor Necrosis Factor, Alpha, Converting Enzyme, Snake Venom-Like Protease, TNF-Alpha Convertase, ADAM-17
Product Info
Storage and Usage
Citations1
Assay Kit Format
Fluorogenic
Supplied As
The ADAM17 Fluorogenic Assay Kit is provided in a convenient 96-well format, with purified ADAM17, ADAM Fluorogenic Substrate, and ADAM assay buffer for 96 enzyme reactions.
Materials Required But Not Supplied

Luminometer or fluorescent microplate reader capable of reading chemiluminescence
Adjustable micropipettor and sterile tips
Rotating or rocker platform

Format
Catalog # Component Amount Storage
  ADAM17 3 µg -80°C Avoid
freeze/
thaw 
cycles!
  ADAM Fluorogenic Substrate (1 mM) 50 µl -80°C
78001 1X ADAM Assay Buffer 5 ml -20°C
79685 96-well black plate 1 Room
Temp
 
UniProt #
P78536
Background

ADAM17 (ADAM Metallopeptidase Domain 17) is part of the ADAM family of disintegrins and metalloproteases. Initially identified as TNF-α converting enzyme (TACE), ADAM 17 has been linked to a number of diverse signaling pathways. It cleaves ectodomains of various transmembrane proteins and regulates cytokine shedding. It also plays a role in inflammatory skin and bowel disease.

References

1. Scheller, Jürgen, et al. 2011. "ADAM17: a molecular switch to control inflammation and tissue regeneration." Trends in Immunology 32(8): 380-387.
2. Blaydon, Diana C., et al. 2011. "Inflammatory skin and bowel disease linked to ADAM17 deletion." New England Journal of Medicine 365(16): 1502-1508.